NYMC Faculty Publications
The Year That Shaped the Outcome of the Ospa Vaccine for Human Lyme Disease
Author Type(s)
Faculty
DOI
10.1038/s41541-022-00429-5
Journal Title
NPJ Vaccines
First Page
10
Document Type
Article
Publication Date
1-27-2022
Department
Pathology, Microbiology and Immunology
Abstract
The expansion of Lyme borreliosis endemic areas and the corresponding increase of disease incidence have opened the possibility for greater acceptance of a vaccine. In this perspective article, we discuss the discovery of outer surface protein A (OspA) of B. burgdorferi, and the subsequent pre-clinical testing and clinical trials of a recombinant OspA vaccine for human Lyme disease. We also discuss in detail the open public hearings of the FDA Lyme disease vaccine advisory panel held in 1998 where concerns of molecular mimicry induced autoimmunity to native OspA were raised, the limitations of those studies, and the current modifications of recombinant OspA to develop a multivalent subunit vaccine for Lyme disease.
Recommended Citation
Dattwyler, R. J., & Gomes-Solecki, M. (2022). The Year That Shaped the Outcome of the Ospa Vaccine for Human Lyme Disease. NPJ Vaccines, 7 (1), 10. https://doi.org/10.1038/s41541-022-00429-5